History was made this week at the UN. The Human Rights Council in Geneva adopted the most ambitious and progressive resolution on drug policy to date, titled ‘Contribution of the Human Rights Council with regard to the human rights implications of drug policy’. While the environment at the Commission on Narcotic Drugs (CND) in Vienna has become increasingly fractious and moribund, this resolution illustrates that progress on drug policy can be made at the UN outside of the Vienna setting. This follows on the heels of the latest ‘omnibus resolution’ that was adopted by a vote at the General Assembly last December, and which also contained important progress on human rights.
There are three clear substantive wins in this Human Rights Council resolution (and more are elaborated in our advocacy note):
While the key substantive gains are of paramount importance, the central operational objective of this resolution is to give a mandate to the Office of the High Commissioner on Human Rights (OHCHR) to produce a report on the human rights impacts of drug policy as a contribution to the upcoming mid-term review of the 2019 Ministerial Declaration that will take place in Vienna at the Commission on Narcotic Drugs (CND) in March 2024. The 2024 mid-term review is the next key moment for the international community to take stock of progress made in international drug policy and pave the way forward for the next five years. Human rights considerations must be front and centre of this review process and this resolution will be instrumental in that regard, especially given that how politically challenging it has been centre the human rights arguments at the CND, and many members states still resist the participation of the UN human rights actors in that setting. The report will also disseminated and discussed at a Human Rights Council intersessional panel discussion which will continue to drive momentum on this nexus in Geneva.
Naturally the difficult negotiations on this resolution inevitably led various concessions being made along the way. For example, the original ambition of the resolution was to create a ‘standing mandate’ for OHCHR to produce periodic reports on the human rights impacts of drug policy. Unfortunately, this was watered down to only one report as a contribution to the mid-term review. Other areas of regression are two amendments tabled respectively by Saudi Arabia and Egypt. The first concerns the primacy of state sovereignty in international law, and the other re-introduces the goal of achieving a ‘society free of drug abuse’. Removing this phrase was one of the key achievements of the latest ‘omnibus resolution’ in New York and the efforts to keep it out of this resolution ultimately failed. However, the vote on the amendment revealed a divided Council, with 25 votes in favour of the amendment, 18 against, and 4 abstentions.
Nonetheless, overall, the gains in this document outweigh the losses, and getting this regressive language back into the text is a pyrrhic victory for governments that favour more punitive approaches as the steps forward taken in this resolution – especially on ‘harm reduction’ – are unprecedented.
This resolution reflects, and highlights, the continuing convergence between drug policy and human rights at the UN. This trend has continued to gain pace and is instrumental in bringing further fracture to the long-revered but now tattered consensus on drugs at the CND in Vienna. UN policy progress outside of Vienna will create much needed pressure on the CND – either to start catching up with the reality that prohibition is a devastating failure, or to continue to fracture and descend into inevitable irrelevance.